Desmopressin is an effective treatment for mixed nocturia with nocturnal polyuria and decreased nocturnal bladder capacity

Hye Won Lee, Myung Soo Choo, Jeong Gu Lee, Choal Hee Park, Jae Seung Paick, Jeong Zoo Lee, Deok Hyun Han, Won Hee Park, Kyu Sung Lee

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

To investigate the efficacy and safety of desmopressin in patients with mixed nocturia, Patients aged ≥18 yr with mixed nocturia (≥2 voids/night and a nocturnal polyuria index [NPi] >33% and a nocturnal bladder capacity index [NBCi] >1) were recruited. The optimum dose of oral desmopressin was determined during a 3-week dose-titration period and the determined dose was maintained for 4 weeks. The efficacy was assessed by the frequency-volume charts and the sleep questionnaire. The primary endpoint was the proportion of patients with a 50% or greater reduction in the number of nocturnal voids (NV) compared with baseline. Among 103 patients enrolled, 94 (79 men and 15 women) were included in the analysis. The proportion of patients with a 50% or greater reduction in NV was 68 (72%). The mean number of NV decreased significantly (3.20 to 1.34) and the mean nocturnal urine volume, nocturia index, NPi, and NBCi decreased significantly. The mean duration of sleep until the first NV was prolonged from 118.4±44.1 to 220.3±90.7 min (P<0.001). The overall impression of patients about their quality of sleep improved. Adverse events occurred in 6 patients, including one asymptomatic hyponatremia. Desmopressin is an effective and well-tolerated treatment for mixed nocturia.

Original languageEnglish
Pages (from-to)1792-1797
Number of pages6
JournalJournal of Korean Medical Science
Volume25
Issue number12
DOIs
Publication statusPublished - 2010 Dec 1

Fingerprint

Nocturia
Polyuria
Deamino Arginine Vasopressin
Urinary Bladder
Sleep
Therapeutics
Hyponatremia
Urine
Safety

Keywords

  • Deamino arginine vasopressin
  • Hyponatremia
  • Nocturia
  • Nocturnal polyuria
  • Urinary bladder

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Desmopressin is an effective treatment for mixed nocturia with nocturnal polyuria and decreased nocturnal bladder capacity. / Lee, Hye Won; Choo, Myung Soo; Lee, Jeong Gu; Park, Choal Hee; Paick, Jae Seung; Lee, Jeong Zoo; Han, Deok Hyun; Park, Won Hee; Lee, Kyu Sung.

In: Journal of Korean Medical Science, Vol. 25, No. 12, 01.12.2010, p. 1792-1797.

Research output: Contribution to journalArticle

Lee, Hye Won ; Choo, Myung Soo ; Lee, Jeong Gu ; Park, Choal Hee ; Paick, Jae Seung ; Lee, Jeong Zoo ; Han, Deok Hyun ; Park, Won Hee ; Lee, Kyu Sung. / Desmopressin is an effective treatment for mixed nocturia with nocturnal polyuria and decreased nocturnal bladder capacity. In: Journal of Korean Medical Science. 2010 ; Vol. 25, No. 12. pp. 1792-1797.
@article{7d9f548daa4b414d90f4cca0c6c549b2,
title = "Desmopressin is an effective treatment for mixed nocturia with nocturnal polyuria and decreased nocturnal bladder capacity",
abstract = "To investigate the efficacy and safety of desmopressin in patients with mixed nocturia, Patients aged ≥18 yr with mixed nocturia (≥2 voids/night and a nocturnal polyuria index [NPi] >33{\%} and a nocturnal bladder capacity index [NBCi] >1) were recruited. The optimum dose of oral desmopressin was determined during a 3-week dose-titration period and the determined dose was maintained for 4 weeks. The efficacy was assessed by the frequency-volume charts and the sleep questionnaire. The primary endpoint was the proportion of patients with a 50{\%} or greater reduction in the number of nocturnal voids (NV) compared with baseline. Among 103 patients enrolled, 94 (79 men and 15 women) were included in the analysis. The proportion of patients with a 50{\%} or greater reduction in NV was 68 (72{\%}). The mean number of NV decreased significantly (3.20 to 1.34) and the mean nocturnal urine volume, nocturia index, NPi, and NBCi decreased significantly. The mean duration of sleep until the first NV was prolonged from 118.4±44.1 to 220.3±90.7 min (P<0.001). The overall impression of patients about their quality of sleep improved. Adverse events occurred in 6 patients, including one asymptomatic hyponatremia. Desmopressin is an effective and well-tolerated treatment for mixed nocturia.",
keywords = "Deamino arginine vasopressin, Hyponatremia, Nocturia, Nocturnal polyuria, Urinary bladder",
author = "Lee, {Hye Won} and Choo, {Myung Soo} and Lee, {Jeong Gu} and Park, {Choal Hee} and Paick, {Jae Seung} and Lee, {Jeong Zoo} and Han, {Deok Hyun} and Park, {Won Hee} and Lee, {Kyu Sung}",
year = "2010",
month = "12",
day = "1",
doi = "10.3346/jkms.2010.25.12.1792",
language = "English",
volume = "25",
pages = "1792--1797",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "12",

}

TY - JOUR

T1 - Desmopressin is an effective treatment for mixed nocturia with nocturnal polyuria and decreased nocturnal bladder capacity

AU - Lee, Hye Won

AU - Choo, Myung Soo

AU - Lee, Jeong Gu

AU - Park, Choal Hee

AU - Paick, Jae Seung

AU - Lee, Jeong Zoo

AU - Han, Deok Hyun

AU - Park, Won Hee

AU - Lee, Kyu Sung

PY - 2010/12/1

Y1 - 2010/12/1

N2 - To investigate the efficacy and safety of desmopressin in patients with mixed nocturia, Patients aged ≥18 yr with mixed nocturia (≥2 voids/night and a nocturnal polyuria index [NPi] >33% and a nocturnal bladder capacity index [NBCi] >1) were recruited. The optimum dose of oral desmopressin was determined during a 3-week dose-titration period and the determined dose was maintained for 4 weeks. The efficacy was assessed by the frequency-volume charts and the sleep questionnaire. The primary endpoint was the proportion of patients with a 50% or greater reduction in the number of nocturnal voids (NV) compared with baseline. Among 103 patients enrolled, 94 (79 men and 15 women) were included in the analysis. The proportion of patients with a 50% or greater reduction in NV was 68 (72%). The mean number of NV decreased significantly (3.20 to 1.34) and the mean nocturnal urine volume, nocturia index, NPi, and NBCi decreased significantly. The mean duration of sleep until the first NV was prolonged from 118.4±44.1 to 220.3±90.7 min (P<0.001). The overall impression of patients about their quality of sleep improved. Adverse events occurred in 6 patients, including one asymptomatic hyponatremia. Desmopressin is an effective and well-tolerated treatment for mixed nocturia.

AB - To investigate the efficacy and safety of desmopressin in patients with mixed nocturia, Patients aged ≥18 yr with mixed nocturia (≥2 voids/night and a nocturnal polyuria index [NPi] >33% and a nocturnal bladder capacity index [NBCi] >1) were recruited. The optimum dose of oral desmopressin was determined during a 3-week dose-titration period and the determined dose was maintained for 4 weeks. The efficacy was assessed by the frequency-volume charts and the sleep questionnaire. The primary endpoint was the proportion of patients with a 50% or greater reduction in the number of nocturnal voids (NV) compared with baseline. Among 103 patients enrolled, 94 (79 men and 15 women) were included in the analysis. The proportion of patients with a 50% or greater reduction in NV was 68 (72%). The mean number of NV decreased significantly (3.20 to 1.34) and the mean nocturnal urine volume, nocturia index, NPi, and NBCi decreased significantly. The mean duration of sleep until the first NV was prolonged from 118.4±44.1 to 220.3±90.7 min (P<0.001). The overall impression of patients about their quality of sleep improved. Adverse events occurred in 6 patients, including one asymptomatic hyponatremia. Desmopressin is an effective and well-tolerated treatment for mixed nocturia.

KW - Deamino arginine vasopressin

KW - Hyponatremia

KW - Nocturia

KW - Nocturnal polyuria

KW - Urinary bladder

UR - http://www.scopus.com/inward/record.url?scp=78649915744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649915744&partnerID=8YFLogxK

U2 - 10.3346/jkms.2010.25.12.1792

DO - 10.3346/jkms.2010.25.12.1792

M3 - Article

C2 - 21165296

AN - SCOPUS:78649915744

VL - 25

SP - 1792

EP - 1797

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 12

ER -